CUL4A
ENSG00000139842
Target class
Unclassified protein
Chromosome
13
Approved drugs
4
Clinical candidates (approved and in development)
5
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- CUL4A
- Gene name
- Cullin 4A
- Gene symbol
- CUL4A
- Protein name
- Cullin-4A (CUL-4A)
- Gene biotype
- Protein coding
- Gene family
- Cullins|MicroRNA protein coding host genes
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 65.56
- Tissue specificity (Gini)
- 0.254
- Tissue specificity (tau)
- 0.617
- KEGG gene identifiers
- hsa:8451
- Protein interaction confidence
- 0.89413
- Protein interaction partners
- 108
- R-HSA-110314
- R-HSA-5696394
- R-HSA-5696395
- R-HSA-5696400
- R-HSA-6781823
- R-HSA-6781827
- R-HSA-6782135
- R-HSA-6782210
- R-HSA-8951664
- End position
- 113267108
- Start position
- 113208193
- Chromosome
- 13
- Strand
- Forward
- Nucleoplasm
- Tissue specificity (tau)
- 0.616776
- Expression inequality (Gini)
- 0.254493
Expression in transcripts per million
- Muscle - Skeletal
- 65.56
- Cells - Cultured fibroblasts
- 49.49
- Testis
- 41.25
- Skin - Sun Exposed (Lower leg)
- 37.4
- Cells - EBV-transformed lymphocytes
- 36.77
Expression in transcripts per million
- Muscle - Skeletal65.56
- Cells - Cultured fibroblasts49.49
- Testis41.25
- Skin - Sun Exposed (Lower leg)37.4
- Cells - EBV-transformed lymphocytes36.77
- Nerve - Tibial36.52
- Cervix - Endocervix36.18
- Uterus36
- Cervix - Ectocervix35.69
- Adipose - Subcutaneous35.63
- Skin - Not Sun Exposed (Suprapubic)35.43
- Thyroid34.71
- Artery - Tibial34.55
- Fallopian Tube33.74
- Vagina33.26
- Esophagus - Gastroesophageal Junction32.32
- Bladder32.01
- Lung31.92
- Artery - Aorta31.9
- Esophagus - Muscularis31.85
- Colon - Sigmoid31.29
- Breast - Mammary Tissue31.26
- Artery - Coronary31.24
- Ovary31.15
- Prostate30.15
And 29 more, listed on the interactive page.
- GO:0000082
- GO:0006974
- GO:0007283
- GO:0016567
- GO:0034644
- GO:0042110
- GO:0042254
- GO:0043161
- GO:0045732
- GO:0097193
- GO:0140627
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0031464
- GO:0080008
- GO:0005515
- GO:0031625
- GO:0061630
- GO:0160072
Related records
Trials (1,854)
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- [Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers]
- 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting
- 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
- A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
- A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
Drugs (5)
- Iberdomide CRL4(CRBN) E3 ubiquitin ligase modulator
- Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
- Lenalidomide hydrochloride monohydrate CRL4(CRBN) E3 ubiquitin ligase modulator
- Pomalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor
- Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor